Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease

Objectives:  Kawasaki disease (KD) is a systemic vasculitis primarily affecting children who are <5 years old. Intravenous immunoglobulin (IVIG) is the standard therapy for KD. However, many patients with KD still show poor response to initial IVIG treatment. This study was conducted to investigate the risk factors for initial IVIG treatment failure in KD.

[1]  M. Mori,et al.  Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. , 2000, The Journal of pediatrics.

[2]  Y. Ohashi,et al.  Coronary risks after high‐dose γ‐globulin in children with Kawasaki disease , 2000 .

[3]  Kuender D Yang,et al.  Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease. , 2007, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[4]  Chin‐Yun Lee,et al.  Epidemiologic Features of Kawasaki Disease in Taiwan, 1996–2002 , 2004, Pediatrics.

[5]  Kuender D Yang,et al.  Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease. , 2002, The Journal of pediatrics.

[6]  K. Durongpisitkul,et al.  Immunoglobulin Failure and Retreatment in Kawasaki Disease , 2003, Pediatric Cardiology.

[7]  M. Mori,et al.  Predictors of coronary artery lesions after intravenous γ-globulin treatment in Kawasaki disease , 2000 .

[8]  Kuender D Yang,et al.  The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease , 2007, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[9]  D. Sherry,et al.  Initial intravenous gammaglobulin treatment failure in Kawasaki disease. , 2000, Pediatrics.

[10]  T. Onodera,et al.  Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. , 2000, The Journal of pediatrics.

[11]  M. Asada,et al.  An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. , 1997, Journal of the American Academy of Dermatology.

[12]  Pei-Jer Chen,et al.  Epidemiologic Features of Kawasaki Disease in Taiwan, 2003–2006 , 2009, Pediatrics.

[13]  Chien-Fu Huang,et al.  Association of lower eosinophil‐related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease , 2009, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[14]  Kuender D Yang,et al.  Coronary artery fistula associated with Kawasaki disease. , 2009, American heart journal.

[15]  J. Newburger,et al.  Gamma globulin re-treatment in Kawasaki disease. , 1993, The Journal of pediatrics.

[16]  Walter R Wilson,et al.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association , 2004, Circulation.

[17]  J. Newburger,et al.  A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. , 1998, The American journal of cardiology.

[18]  T. Matsuishi,et al.  Serum alanine aminotransferase concentrations in patients with Kawasaki disease , 2003, The Pediatric infectious disease journal.

[19]  Kuender D Yang,et al.  Kawasaki disease: infection, immunity and genetics. , 2005, The Pediatric infectious disease journal.

[20]  M Takahashi,et al.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. , 1991, The New England journal of medicine.

[21]  Kuender D Yang,et al.  Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. , 2003, Pediatrics.

[22]  J. Burns,et al.  Elevated gamma-glutamyltransferase concentrations in patients with acute Kawasaki disease. , 1998, The Pediatric Infectious Disease Journal.

[23]  J. Newburger,et al.  Resistance to intravenous immunoglobulin in children with Kawasaki disease. , 2008, The Journal of pediatrics.

[24]  T Enright,et al.  Kawasaki syndrome. , 1990, Annals of allergy.

[25]  J. Newburger,et al.  Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. , 1998, The Pediatric infectious disease journal.

[26]  J. Newburger,et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. , 1986 .

[27]  H. Yanagawa,et al.  A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. , 1974, Pediatrics.

[28]  Y. Kohno,et al.  Prognostic Impact of Vascular Leakage in Acute Kawasaki Disease , 2003, Circulation.